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Abstract
Human cancers harbor substantial genetic, epigenetic, and transcriptional changes,
only some of which drive oncogenesis at certain times during cancer evolution.
Identifying the cancer-driver alterations amongst the vast swathes of “passenger”
changes still remains a major challenge. Transposon and CRISPR screens in vivo
provide complementary methods for achieving this, and each platform has its own
advantages. Here, we review recent major technological breakthroughs made with
these two approaches and highlight future directions. We discuss how each genetic
screening platform can provide unique insight into cancer evolution, including intra-
tumoral heterogeneity, metastasis, and immune evasion, presenting transformative
opportunities for targeted therapeutic intervention.
Introduction
Large-scale human tumor sequencing projects have been invaluable in establishing the
genetic landscapes of many cancers [1]. These have identified hundreds of recurrently
mutated genes, as well as copy-number variations, transcriptional changes, and epigen-
etic alterations, but the role of most of these alterations in oncogenesis is unknown.
Cancer genomics primarily inform which mutations are present in cancer but have
limited power to tell us which of these are functionally important [2, 3]. Therefore,
complementary approaches are required to understand the functional role of such gen-
etic changes, particularly of those that occur less frequently (so-called long-tail mu-
tated genes) and of non-mutated putative cancer genes, and importantly how genetic
drivers cooperate with one another for cancer evolution.
Early insertional mutagenesis screens in mice used retroviruses, yet viral tropism pre-
cluded their widespread use for cancer investigation [4, 5]. A fruitful approach over the
last decade to pinpoint genetic drivers of cancer is through in vivo transposon muta-
genesis, forward genetic screening in mice. DNA transposons are genetic elements that
can shift positions within a genome. Sleeping Beauty (SB) and, more recently, piggyBac
(PB) mutagenesis have been deployed to elucidate the functional drivers of many can-
cers, unveiling molecular changes underpinning cancer initiation, progression, metasta-
sis, and resistance to treatment [6, 7].
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Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associ-
ated protein 9 (Cas9) is a prokaryotic, adaptive immune system that was adapted as a
genome-editing tool in eukaryotic cells [8, 9]. CRISPR screens provide a complemen-
tary approach to transposon mutagenesis and RNAi screens for uncovering genetic
mechanisms of cancer evolution. In recent years, CRISPR techniques have evolved to
enable screening strategies to be performed in vivo [10, 11]. The simplicity by which
gene editing can be performed and the low off-target effects have made CRISPR par-
ticularly attractive as a platform for genomic screens. Alternative variants of the Cas
nuclease have afforded the ability to conduct gain- and loss-of-function screens for de-
fining oncogenes, tumor suppressor genes (TSGs), therapeutic vulnerabilities, and im-
munotherapy targets [12–15], as well as to functionalize the non-coding genome.
In this review, we focus our discussion on recent developments in transposon muta-
genesis and CRISPR cancer screens in vivo, and the relative advantages of these com-
plementary tools for discovery of cancer genes. We highlight future directions for the
field to maximize the translational impact of these powerful techniques in order to de-
velop a comprehensive functional understanding of cancer genes, including their role
in tumor evolution and metastasis, and to reveal opportunities for therapeutic
intervention.
Transposon mutagenesis screens in cancer
DNA-transposons are genetic elements that move through the genome by a “cut-and-
paste” mechanism and are generally inactive in mammalian cells in nature [16]. How-
ever, through genetic engineering, several groups have generated active recombinant
transposons that can be used as insertional mutagens in mice and other vertebrates
[17–19]. They consist of two components: the transposon vector and the transposase
enzyme. When these are present in the same cell, the transposase recognizes the ter-
minal repeats of the transposon and excises it from the donor locus. The transposon
can then insert itself elsewhere in the genome creating a mutation and be used as a tag
to pinpoint the genes it mutates.
For cancer screens, transposons have been equipped with genetic elements that en-
able them to induce gain-of-function or loss-of-function mutations, depending on their
orientation and position relative to the target gene (Fig. 1a). To perform insertional
mutagenesis screens in mice, two types of mouse lines were engineered: “transposon
mice” containing various transposon copies (ranging from one to a few hundred) on a
single chromosome; and “transposase mice” that express the transposase in a constitu-
tive or tissue-specific manner. By predisposing to cancer initiation using a mouse trans-
genic line carrying a known tumorigenic allele, such as a Trp53 mutation [21], and
then crossing in transposon and transposase alleles, one can map the subsequent trans-
poson “common insertion sites” (CIS; genes “hit” more frequently than would be ex-
pected by chance) of resulting tumors to elucidate the functional mutations that
cooperate with the predisposing mutation to drive cancer. With SB and PB, this was
initially done using a constitutive approach (with SB or PB expressed throughout the
body), giving rise to multiple cancers in the same mice [22, 23]. Conditional SB, and
more recently PB, conditional screening strategies have successfully enabled exploration
of tissue-specific cooperating groups of genes in several cancers [24–32]; these screens
typically use Cre-transgenic mouse lines to express the transposase in target tissues.
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SB and PB are the most widely used transposons for cancer screens. SB transposons
derive from the salmonid Tc1-Mariner elements [17]. Modifications to the terminal re-
peats and transposase were made early on in order to improve transposition efficiency
Fig. 1 Transposon mutagenesis and CRISPR-induced genetic and epigenetic alterations. a Sleeping beauty
(SB) and piggyBac (PB) transposons carry a promoter upstream of a splice donor (SD) sequence that can
lead to overexpression of downstream genes. This is equivalent to activation of proto-oncogenes.
Transposons also contain splice acceptors (SAs) followed by bidirectional polyadenylation (polyA) signals to
cause termination of transcripts that arise when inserted into the body of a gene (primarily in introns). This
is important for inactivating tumor suppressor genes (TSGs). b CRISPR-Cas9 is a two component system: the
single guide RNA (sgRNA) directs the Cas9 nuclease to a complementary sequence in the genome where
Cas9 will induce a double-strand break (DSB). The target genomic locus must be followed by a 5′-NGG-3′
motif (protospacer adjacent motif, PAM) for Cas9 to function. DSBs are resolved by non-homologous end-
joining, or by homology directed repair (HDR) in the presence of a DNA repair template, which can be
exploited to introduce precise genetic modifications or exogenous sequences. Other variants of the Cas
nuclease have been engineered to function in mammalian cells, including a nuclease-deficient Cas9 (dCas9)
fused to various effector domains: a transcriptional activator (A) for activation of gene expression, a
transcriptional repressor (R) to knockdown gene expression [20], epigenetic effectors such as DNA
methyltransferases (DNMT) for methylation, and base editors such as cytosine base editors (CBE) for
generating point mutations
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[18, 33, 34]. SB integrates into TA dinucleotides that are duplicated upon integration
and leave behind a 2–5-bp “footprint” mutation after mobilization [35]. Thus, insertions
that were driving oncogenesis can still be identified through exome or genome sequencing
even if the transposon has subsequently mobilized into another site [24]. However, foot-
prints lead to varying degrees of genetic disruption, contributing to “noise” in the screen.
SB also has a tendency for “local hopping,” that is, excision and reintegration of the trans-
poson into a neighboring region of the same chromosome. This is a disadvantage for can-
cer screens because it leads to passenger mutations near cancer genes [36], and must be
considered when analyzing screening data [37, 38]. Further characteristics of the SB sys-
tem have been reviewed in detail elsewhere [19, 39–41].
The PB transposon is naturally found in the cabbage-looper moth Trichoplusia ni
[42]. Efforts were made to adapt PB for mammalian systems [42], and specifically for
forward genetic screens of cancer both in vitro and in vivo [36, 43, 44]. The higher
transposition efficiency, larger cargo capacity, and lower rate of local hopping in com-
parison with SB make PB particularly useful for genome-wide screening. PB has a pref-
erence for inserting into TTAA sites [45] and does not leave a footprint after
mobilization unlike SB. The increased tendency for PB to insert into open chromatin
regions [43, 46, 47] relative to SB enables the identification of non-coding regions that
may contribute to cancer. For example, a novel Cdkn2a-cis regulatory region was iden-
tified as a contributor to pancreatic cancer development by PB insertions [48].
Altogether, PB and SB are complementary tools with the deployment of both being
more likely to lead to saturating mutagenesis and maximal gene discovery in cancer [48].
CRISPR screens in cancer
Technologies for genetic manipulation of mammalian genomes based on engineered
nucleases have evolved rapidly over the last decade. The CRISPR-Cas9 system consists
of two components, the endonuclease Cas9 from Streptococcus pyogenes (SpCas9) and a
single guide RNA (sgRNA). Cas9 is directed to cleave any desired genomic locus com-
plementary to a unique sgRNA sequence. Thus, one can change the genomic target of
Cas9 by simply changing the sgRNA sequence [49] (Fig. 1b). Introduced double-strand
breaks (DSBs) can be repaired by error-prone non-homologous end joining (NHEJ),
leaving small insertions and deletions (indels) which often cause loss of function of the
target gene [50]. The co-expression of Cas9 and multiple sgRNAs within the same cell
(multiplexing) enables not only the induction of more complex genomic alterations
[51] (i.e., translocations, inversions, duplications, and large deletions), but also delinea-
tion of complex combinatorial gene networks [10, 52, 53].
Besides Cas9, other RNA-guided DNA endonucleases have been engineered with dif-
ferent features, as well as RNA-guided ribonucleases to manipulate cellular transcripts
[54]. Moreover, a nuclease-deficient Cas9 (dCas9) has been fused to a variety of effector
domains: transcriptional activators (e.g., VP64) to mediate gene activation (CRISPRa)
[55], transcriptional repressors (e.g., KRAB) to knockdown gene expression (CRISPRi)
[20], DNA methyltransferases (e.g., DNMT3A or TET1) or histone-modifying enzymes
(e.g., p300) for regulating the epigenome [56], and base-editors (e.g., AID) for precise
single-nucleotide exchanges [57–59]. Such base editors enable the introduction of point
mutations in DNA (or RNA) without making DSBs, therefore not requiring NHEJ and
leaving no indels [60]. Although DNA editing can also be achieved by supplying a
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donor DNA template whilst inducing a DSB with Cas9, this relies on homology-
directed repair (HDR) which is mainly limited to G2 and S phases of the cell cycle and
has low efficiency; efforts to increase the efficiency of HDR for DNA editing may facili-
tate its use for in vivo screens.
A number of studies have demonstrated the usefulness of CRISPR for genome-wide
and focused cancer screens in vitro [55, 61–64]. In such studies, cancer cells are trans-
duced with customized lentiviral libraries carrying up to thousands of sgRNAs against
any genes of interest. After biological selection for a phenotype, such as resistance to a
drug, DNA from cells is sequenced to define enriched (positive selection screen) and/or
depleted (negative selection screen) sgRNAs driving or preventing this phenotype re-
spectively. Such screens have enabled exploration of genetic underpinnings of many
cancer phenotypes, including genes essential for cancer cell survival and growth [61,
65, 66], modifiers of drug resistance [64, 67], and synthetic lethal genetic interactions
[68, 69]. RNAi screens have also been used for investigating cancer phenotypes in vivo,
in particular by using lentiviral or retroviral transduction of short hairpin RNAs
(shRNAs) to achieve genetic knockdown [70]. Although pooled RNAi screens have
been instrumental in functional interrogation of cancer genes and drug resistance
mechanisms [71], CRISPR provides generally fewer off-target effects compared with
RNAi and also extra versatility for genetic manipulation, including not only knock-
down, but knockout, activation, methylation, and base editing [72]. Detailed compari-
sons of CRISPR and RNAi screens have been reviewed elsewhere [73].
Despite the success of CRISPR in vitro screens, an in vivo approach is needed to ac-
count for interactions between cancer and host cells, including the immune micro-
environment [74, 75]. The revolutionization of cancer treatment by immunotherapies
underscores the importance of fully recapitulating tumor microenvironments which
can only be accomplished in vivo. In the same way that a CRISPR-induced mutagenized
pool of cells can be propagated in cell culture, it can also be implanted into mice for
in vivo screens. These transplant models are attractive because of the comparative ease
of gene editing with CRISPR in vitro prior to establishing an in vivo context. However,
these models do not give rise to de novo tumors from normal cells at the organ site in
situ, and they usually rely on immunodeficient host mice to facilitate the engrafting
efficiency.
Direct in vivo mutagenesis of somatic cells provides a more faithful recapitulation of
human cancer development than transplant models [76]. In these autochthonous
mouse models, tumor cells originate de novo from endogenous cells in the target tissue
and evolve towards malignancy in their natural microenvironment, under the surveil-
lance of the host immune system. Moreover, induced mutations accumulate in a de-
fined and uniform host genetic background, which aids the interpretation of their
functional role in cancer.
Transposon mouse models provide an autochthonous setting for cancer development,
but for CRISPR screens to be performed in these conditions, they require Cas9 and
sgRNAs to be delivered directly to the target tissue. To facilitate this, transgenic mice
expressing Cas9 in the germline, constitutively or in a tissue-specific (Cre-dependent)
manner, have been developed [77]. These models can also overcome immunogenicity
of Cas9 when this is introduced into mammals [78]. Initial studies with CRISPR-Cas9
in vivo focused on targeting one to three key cancer genes and provided proof of
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principle for the use of CRISPR to directly induce cancer in vivo. To date, efficient de-
livery of sgRNA libraries to different tissues of adult mice has been achieved through
several methods, allowing for high-throughput discovery and validation of cancer genes
in vivo.
A simple way to deliver CRISPR libraries into cells in vivo is through DNA transfec-
tion. For example, hydrodynamic injection of SB or PB transposon constructs carrying
a library of sgRNAs (along with Cas9) allows for multiplex mutagenesis and cancer in-
duction [79, 80]. As the transposon gives stable integration of the CRISPR constructs
into the host genome, the sgRNA cassette can be subsequently identified as a readout.
Transient electroporation of sgRNAs can also be performed [81, 82], with fewer off-
target effects due to lack of stable Cas9 and sgRNA expression. These methods of
transfection also allow for delivery of multiple CRISPR plasmids into each cell, enabling
random multiplexed mutagenesis [79].
The use of viral vectors has extended the range of target tissues amenable to CRISPR
screens. Integrating viruses such as lentivirus accommodate a relatively large DNA
cargo (~ 8–10 Kb) and their ability to self-integrate into the genome. For example,
lentiviral sgRNA/Cre pools targeting TSGs were administered intratracheally into
conditional Cas9 and KrasG12D transgenic mice to generate lung tumors [83]. Non-
integrating viral vectors, in particular single-stranded adeno-associated viruses
(ssAAVs), albeit presenting a reduced carrying capacity (~ 4.7 Kb), have higher trans-
duction rates compared with lentivirus and low immunogenicity [84]. Given the limited
cargo capacities of viral vectors, it is important to maximize the usefulness of the plas-
mids being delivered; as such, Cas9 knock-in mice, including conditional ones with
tissue-specific Cas9 expression, obviate the need to deliver Cas9 with a viral vector and
also help prevent immune clearance of Cas9-expressing cells when Cas9 is delivered in
this way [77]. Alternatively, smaller versions of Cas9, such as Staphylococcus aureus
Cas9, can be delivered together with sgRNAs using viral vectors [85]. Finally, nanopar-
ticles, including those based on lipid or gold, have a large cargo capacity and can be
used for delivery of Cas9 and sgRNAs, typically with low immunogenicity [86–90]; early
results show efficient genome editing in vivo with such nanoparticle delivery
techniques.
In sum, CRISPR screens can now be deployed to examine many aspects of cancer
genetics in an in vivo setting, with newer developments promising to provide unprece-
dented biological insight.
Comparison of transposon and CRISPR cancer screens
Transposon and CRISPR screens are complementary tools in cancer. In contrast with
transposon mutagenesis where there is random genome-wide screening for cancer
genes, CRISPR offers additional versatility by allowing for focused genetic screens in
cancer where genes of potential interest are pre-specified (Fig. 2). CRISPR-induced mu-
tations are set after the time of sgRNA library delivery, whereas with transposon muta-
genesis mutations continue to occur during a screen due to transposition. This ability
to accumulate mutations throughout tumor evolution mimics human cancer progres-
sion and allows for the interrogation of genes at different disease stages. For example,
EGFR-initiated gliomas were noted to have high genomic instability including large
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chromosomal deletions, presumably reflecting the need for additional driver events: PB
enabled pinpointing of these collaborating cancer genes [91].
A common feature of CRISPR screens is that they are purely loss-of-function in the
context of Cas9, or purely gain-of-function when CRISPRa is employed (Table 1). This
differs from most transposon mutagenesis screens which use SB or PB transposons that
can either activate or inactivate genes in the same tumors. Although having both gain-
and loss-of-function capability in the same screen is advantageous, computational inter-
pretation of which genetic hits are oncogenes or TSGs can be challenging, particularly
for CIS with few insertions. Consequently, exclusively inactivating transposon platforms
have been designed that simplify downstream interpretation with all hits being putative
TSGs; this has been informative in identifying new B cell lymphoma drivers with PB
Fig. 2 CRISPR and transposon mutagenesis screens enable cancer gene identification in vivo. Left: a typical
pooled, sgRNA CRISPR library is transduced into Cas9-knockin mice, leading to the loss of a TSG in each cell,
driving oncogenesis. Multiplexed delivery of sgRNA constructs can alternatively be achieved leading to
simultaneous editing of multiple TSGs (not represented). Right: mice harboring transposons and transposase
develop spontaneous tumors due to transposon-induced activating and inactivating mutations. Both
oncogenes and TSGs can be identified by deep sequencing of transposon hits at different stages of tumor
progression, revealing genetic routes of cancer evolution. Symbol notation: cross = inactivating mutation;
bent arrow = activating mutation; different colors denote mutations in different cancer genes
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[92]. We anticipate the development of mouse lines carrying transposons with purely
activating sequences will facilitate genome-wide screens focused on characterizing
oncogenes.
Undesired genetic effects also differ between transposons and CRISPR; although
CRISPR-Cas9 has low off-target effects (unintended modifications at other sites in the
genome) in comparison with prior RNAi screens [93–95], these warrant consideration
in screens, justifying the use of multiple sgRNAs per gene and of new computational
tools to improve sgRNA design [96–102]. Unintended on-target effects have also been
noted with Cas9 [103]. Cas9 expression has been found to activate the p53 pathway
and select for TP53-inactivating mutations, presenting a potential caveat of Cas9 tumor
models [104]. Aside from footprint mutations that occur with SB and local hopping
with both transposon types, SB and PB have integration preferences that may present
false positives in cancer screens, requiring downstream validation studies to exclude
these. Regarding the nature of mutations, with CRISPR, both alleles of a diploid cell
can become mutated, whereas transposons typically cause heterozygous mutations; this
can be advantageous meaning transposon screens are able to detect haploinsufficient
tumor suppressors, particularly in the context of a Bloom-deficient background which
Table 1 Comparison of transposon mutagenesis and CRISPR screens in vivo
Feature CRISPR Transposon
Cancer model
quality
Transplantation models: limited by lack of
immune system.
Autochthonous models: high quality.
High-quality given autochthonous nature.
Tissue delivery
of
components
Can be technically challenging. Options
include:
- Transfection, with or without PB/SB:
allows multiplexing; limited to certain
organs.
- Lentivirus or AAV: wide range of tissues
are accessible; relatively limited cargo
capacity.
- Nanoparticles: high cargo capacity, low
immunogenicity.
Constitutive and conditional transposase mouse
knock-in alleles are available. No further delivery of
exogenous components is required.
Efficiency of
mutations
High efficiency in vitro (for transplantation
model).
In vivo mutagenesis has typically lower
efficiency than in vitro.
High efficiency of gene disruption in vivo; gene
activation efficiency is variable. Therefore, TSGs are
more identifiable than oncogenes1.
Types of
mutations
Disruptive (indels)/knockout.
Transcriptional activation/repression.
Translocations/deletions.
Point mutations.
Disruption or activation of expression.
Drop-out screens are not possible.
Alleles
targeted
Can induce mutations in both alleles of
diploid cells
Usually only one allele is mutated in diploid cells.
Unwanted
genetic effects
Low off-target effects.
On-target unintended effects may occur.
Local hopping
Footprint mutations with SB.
Genome
coverage in
screen
Focused or genome-wide libraries.
High library coverage can be challenging
to achieve in vivo.
Whole-genome including non-coding regions.
PB favors open chromatin.
SB and PB have differing integration preferences.
Time to
conduct
screen
Relatively short: direct injection of CRISPR
components into tissues is required.
Relatively long: compound mutant mice (typically
three or four alleles) need generating.
Costs of
screen
Relatively low. High costs due to long mouse breeding times.
1Gene disruption is more likely given that the position and orientation of the transposon relative to the inserted gene
are less critical than for gene activation
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favors loss of heterozygosity of inactivating mutations by increasing mitotic recombin-
ation [105, 106]. Moreover, compared with transposon mutagenesis, CRISPR is able to
recapitulate a larger repertoire of genetic changes seen in human cancer, including
point mutations [107–109], and allows for negative-selection (“drop-out”) screens.
CRISPR in vivo screens have associated challenges. It is often difficult to achieve high
library coverage for genome-wide in vivo screens given that very many cells would need
to be transduced with sgRNAs to maintain library representation, meaning that investi-
gators typically choose to use focused sgRNA libraries for such screens. Moreover, the
multiplicity of infection is difficult to control, delivery efficiency rates can be low, the
accessibility of the target tissue to CRISPR libraries may be challenging, and the host
immune response to delivery vectors may render the complete clearance of the targeted
cells. Transposon mutagenesis screens lack these difficulties, allowing the study of
virtually any cancer type with genome-wide coverage, without such immune responses,
although transposon screens are more time-consuming given the need for crossing
multiple alleles.
We next discuss how CRISPR and transposons screens can be harnessed for under-
standing cancer heterogeneity, metastasis, and resistance to treatment (Fig. 3).
Truncal drivers and intratumor heterogeneity
Intratumor heterogeneity, resulting from branching tumor evolution, complicates ef-
forts to decipher important drivers of cancers and therefore to develop effective preci-
sion therapies [110–112]. Within a tumor, there is phenotypic variation in cancer cell
and immune cell types, in addition to different subclonal mutational and transcriptional
signatures that influence these phenotypes [113]. An attractive therapeutic approach is
to target the “truncal drivers,” those genetic changes that are present at the trunk of
the cancer evolutionary tree and which sustain growth of multiple subclones rather
than more minor changes present only in small subpopulations of tumor cells [114,
Fig. 3 Applications of CRISPR and transposon mutagenesis for in vivo cancer screens. Cancer is typically
genetically and phenotypically heterogeneous, and immune cells in the microenvironment play a pivotal
role in oncogenesis. Key areas for investigation of cancer by in vivo screens include genetic mechanisms of
tumor heterogeneity, metastasis, immune evasion, and resistance to treatment. “T” = transposon
mutagenesis; “C” = CRISPR
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115]. These truncal mutations will be present in the majority of cells within a tumor,
providing potentially attractive neo-antigens for immunotherapy and targets for inhibit-
ing oncogenic signaling [116].
Transposon mutagenesis is a powerful tool for defining truncal driver genes, given
that such genes will have transposon integrations with the highest sequence read
counts (suggesting high clonality), making them readily discernible. This has been
exploited by multiple studies with SB. For example, a hepatocellular carcinoma (HCC)
SB screen in a chronic hepatitis B autochthonous model yielded 21 truncal drivers
compared with 2860 candidate late-stage drivers; 1199 genes were related to hepatocel-
lular metabolism, including truncal drivers such as Pten, Adk, and Zbtb20, suggesting a
prominent role for aberrant metabolism in HCC [117]. Takeda et al. utilized different
predisposing mutations (Apcmin, KrasG12D, Trp53R172H, and Smad4+/−) in SB screens to
investigate the genetic evolution of gastrointestinal tumors in autochthonous models
[118, 119]. These screens yielded 142 candidate trunk driver genes. Apc, an antagonist
of the Wnt pathway, was the most frequently mutated trunk gene in Apc-, Kras-, and
Trp53-mutant tumors, consistent with APC loss being the main mechanism for initi-
ation of human CRC. By contrast, Smad4-mutant tumors presented frequent trunk in-
sertions in the wild-type Smad4 allele along with mutually exclusive activating
insertions in Wnt receptor agonist Rspo1 and Rspo2, highlighting different mechanisms
for WNT signaling activation operating in this genetic context.
These studies have proved successful for discriminating truncal driver genes amongst
the many genes that are hit by transposition. However, transposon insertions were
identified based on PCR amplification of transposon-containing fragments obtained
from enzymatic digestion of tumor DNA, which results in amplification biases due to
the uneven genomic distribution of restriction enzyme recognition sites. Alternatively,
acoustic shearing of tumor DNA mitigates this bias by fragmenting DNA at random
points, allowing for a semiquantitative analysis of the relative clonality of individual in-
sertions within heterogeneous tumors [48, 92, 120, 121]. Moreover, Mann et al. have
developed SBCapSeq, a method to identify SB transposon insertion sites from single
tumor cells [122]. Application of SBCapSeq to an SB model of myeloid leukemia en-
abled single-cell resolution of transposon hits, identifying cooperating trunk drivers Erg
and Ghr, and Notch1 and Ets1 in major dominant subclones. This approach can
conceivably be adapted to PB.
Most transposon mouse lines have multiple copies of the transposon mobilizing
in each cell, presenting a challenge for identifying the key molecular players
amongst tumor subclones. To help resolve this complexity, de la Rosa et al.
employed a single-copy of the SB transposon and coupled its mobilization to the
inactivation of one Pten allele within each cell on a Bloom-deficient background.
The analysis of prostate, breast, and skin tumors arising de novo from these mice
identified novel TSGs cooperating with Pten in these cancer types, of which
Zbtb20, Celf2, Pard3, Akap13, and Wac were further validated as prostate cancer
drivers [105, 123]. This model had advantages compared with multiple-copy trans-
poson models: having only one copy of the transposon per cell reduced passenger
mutations, and transposition was coupled to Pten inactivation within each genome,
which may increase the sensitivity of the screen for identifying Pten-cooperative
cancer genes. Single-copy models can be further exploited to interrogate
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intratumor heterogeneity by dissecting the clonality of transposon insertions even
from bulk sequence analysis.
CRISPR in vivo screens serve as an essential tool for investigating how tumor sub-
clones interact with one another in controlled experimental settings. The AAV-CRISPR
platform facilitates functional interrogation of intratumoral heterogeneity, as demon-
strated by recent examples. Stereotaxic delivery into the brain of conditional Cas9 mice
of an ssAAV sgRNA library, targeting Trp53 together with recurrently mutated candi-
date cancer genes, induced tumors in an autochthonous setting that recapitulate hu-
man glioblastoma [84]. The same AAV vectors were also injected intravenously for the
study of liver cancer [14]. Given the higher transduction efficiency of ssAAV, tumors
had multiple mutations, and co-operative driver events could be identified by determin-
ing patterns of co-occurring CRISPR-induced mutations. These brain and liver cancers
were composed of competing subclones, mimicking the genetic complexity of intratu-
moral heterogeneity seen in human cancers that is often not recapitulated in other
genetically engineered mouse models [32]. The clonal dynamics of these tumors are
simpler to interpret because of the relatively few mutated genes observed compared
with human cancer, and that the genes are pre-specified by the library shifting focus to
a core set of genes-of-interest.
Single-cell sequencing technologies are rapidly evolving. We anticipate that single-
cell RNA-sequencing (scRNA-seq) will allow characterization of cancer genotype-
phenotype links at high resolution for understanding tumor heterogeneity and truncal
driver effects in transposon cancer models. Advances in computational tools have
improved the detection of fusion transcripts, which are produced by transposon in-
sertions: these transcripts are initiated by the transposon and splicing to down-
stream exons, or they are initiated by the endogenous cell promoter and splicing
to the transposon [124, 125]. Detection of these transcripts as part of transcrip-
tomic analysis enables comparison of transposon hits with tumor gene expression
profiles to link genotypes with cancer phenotypes, although this has yet to be
performed for single cells.
To pinpoint cells derived from a common ancestor for the purposes of lineage tra-
cing, DNA barcodes can be integrated in CRISPR vectors to deconvolute bulk tumor
populations into individual clones with specific mutations through deep sequencing
[83, 126, 127]. Recent integration of pooled CRISPR screens with single-cell RNA se-
quencing has allowed linking of each gene knockout with its effect on the cell’s tran-
scriptome, disentangling cellular heterogeneity at ultra-high resolution [128]. Several
methods (Perturb-Seq, CRISP-seq, or CROP-seq) have been engineered to accomplish
this, all relying on the indirect index of the sgRNAs with poly-adenylated unique mo-
lecular identifiers that can be detected by mRNA-seq [129–131]. Newer innovations
have been introduced which allow multiple distinct sgRNAs expressed in each cell to
be directly sequenced alongside their transcriptomes (Direct-capture Perturb-seq)
[132]. This technology circumvents the limitations associated with the indirect barcod-
ing of sgRNAs of previous methods (including poor scalability, dependence on special-
ized vector systems, and high cost) and allows high-throughput investigations of
genetic interactions. These methods have been employed in cell lines, yet application to
cancer cells in de novo tumors is eagerly anticipated. Such innovations are likely to
yield deeper insights into intra-tumor heterogeneity from CRISPR screens.
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Genetic determinants of metastasis
The development of metastases at sites distant from the primary tumor is a hallmark of
cancer [133], portends major treatment challenges, and is a leading cause of cancer-
related deaths. Metastasis depends on complex genetic interactions that are still poorly
understood, particularly in comparison with underlying primary tumors. Metastasis re-
quires a sequence of events that includes invasion of cancer cells into surrounding tis-
sues, seeding of these cells into the blood (and lymphatic) circulation, and deposition of
these cells into distant tissues to form micro-metastases and subsequently full-blown
metastases reaching threshold for clinical detection [134]. In vivo cancer screens are
paving the way for understanding these interactions between driver genes in metastatic
cancer evolution.
An SB screen designed to elucidate cancer genes in medulloblastoma (a brain cancer)
utilized heterozygous Ptch1 and heterozygous Trp53 mouse backgrounds to mimic the
human cancer in an autochthonous context. These screens discovered high genetic di-
vergence between primary medulloblastomas and their metastases, with the metastases
containing driver events from a restricted subclone of the primary tumor. Clonal inser-
tions were observed in oncogenes Notch2 and Tert in primary tumors but not metasta-
ses, whereas insertions were present in PI3K pathway genes such as Pten, Akt2, and
Pik3r1 exclusively in metastases. These results could imply that targeted therapies
against truncal drivers of primary medulloblastomas will not remove the metastases
[135]. An osteosarcoma SB screen in mice with and without Trp53 somatic loss re-
ported 232 CIS genes associated with de novo primary cancer development and 43 CIS
genes associated with metastases (for example, Pten, Nf2, and Snap23). Most me-
tastases shared several genetic insertions with matching primary osteosarcomas,
suggesting shared clonal evolution of primary and metastatic tumors during onco-
genesis; some metastases however shared few insertions with the primary tumor,
implying an early metastatic event in those cases and highlighting heterogeneity in
tumor evolutionary forces [136]. Transposon screens can also help define molecular
determinants of other processes needed for metastasis such as the epithelial-
mesenchymal transition (EMT) [134, 137].
In comparison with transposon mutagenesis, where transposons continue to mobilize
even after cancer genes are “hit,” CRISPR mutations are generated right at the begin-
ning of a cancer screen. This means that for transposon screens, additional driver genes
can be pinpointed that yield metastases that may not be present in the primary tumors.
With CRISPR, the initial group of pre-specified sgRNAs in the library sets the limit for
driver mutations (although selection pressures continue to direct tumor evolution),
allowing a screen to focus specifically on one stage of cancer evolution, such as metas-
tasis. Repeated delivery of CRISPR libraries may allow interrogation of multiple disease
stages, although it is likely to be technically challenging to target the same cells. One of
the first CRISPR in vivo cancer screens introduced a genome-wide loss-of-function
sgRNA library into a previously non-metastatic mouse cancer cell line expressing Cas9,
then subcutaneously transplanted these cells into immunocompromised mice, and
monitored them for lung metastases [138]. Genetic sequencing for the sgRNAs in
metastases enabled identification of genes functionally promoting cancer dissemination.
Circulating tumor cells (CTCs) in the bloodstream are recognized as an intermediate
stage of metastasis, with a fraction of these cells being capable of colonizing distant
Noorani et al. Genome Biology          (2020) 21:204 Page 12 of 22
organs and initiating metastases [139]. CRISPR screens have provided a new opportun-
ity for studying the biology of CTCs. A recent demonstration of this comes from a
genome-wide gain-of-function screen in a mouse transplant model using the CRISPRa
system in CTCs derived from breast cancer patients. Screen hits from metastases were
enriched for ribosomal proteins and regulators of translation. In particular, overexpres-
sion of one candidate, RPL15, led to increased metastasis in mice [140]. These gain-of-
function genetic targets are likely to be more susceptible to drug targeting than those
that are loss-of-function, which typically require indirect approaches for therapeutic
targeting.
Given that metastases generally require additional driver mutations compared with
early tumor stages [141], a promising novel approach for deciphering metastasis drivers
is by the use of an alternative version of Cas, CRISPR-associated endonuclease in Prevo-
tella and Francisella 1 (Cpf1, also called Cas12a). Cas12a enables genome editing at
multiple loci (up to 25 so far) to occur simultaneously using a single CRISPR array
[142, 143]. A screen used this system to generate double knockouts in a cancer cell line,
with a library of candidate metastasis-causing genes [144]. Transplantation of these
cells into the skin of immunocompromised mice led to primary tumors and lung me-
tastases, sequencing of which revealed gene pairs clonally selected for in metastatic de-
velopment such as Nf2 and Trim72 double knockouts. This platform will thus shed
further light into the cooperative genetic partners that promote cancer dissemination.
Given that CRISPR-mediated mutations rely on double-strand breaks, having many of
which may lead genome instability and possible cell death, further exploration of RNA-
guided ribonucleases is warranted as a potential option for multiplexed screens [54].
Genes influencing response to treatment
A key factor affecting survival of cancer patients is that cancers develop resistance to
therapeutic drugs, driven by novel alterations in cancer cells that selectively provide a
survival advantage in the presence of drugs. Clonal dynamics ensure that cancers evolve
in a way that makes them resistant to those drugs (such as EGFR inhibitors for EGFR-
mutant colorectal cancer [145]), demanding the use of newer agents for recurrent tu-
mors. The genome of these “end-stage” cancers is typically complex given the wealth of
genetic and epigenetic alterations accumulated during their life history (most of which
are of uncertain significance). This makes discerning genes driving therapeutic resist-
ance all the more challenging. Functional genomic screens are increasingly being
adapted to solve these problems, including drivers of cancer relapse after treatment,
and of sensitivity and resistance to drugs.
An illustrative approach comes from an SB screen for genes giving resistance to ther-
apy in a “humanized” autochthonous mouse model of heterozygous Ptch1 medulloblas-
toma [146]. The SB-primary tumors were microsurgically removed and the mice
treated with radiotherapy, reflecting the standard of care in human patients. Genetic se-
quence analysis of the recurrent tumors revealed different CIS genes between primary
and relapsed medulloblastomas. For example, clonal insertions in Arid1b and Tcf4 were
observed in metastases but not in primary tumors. Moreover, the dominant clone of re-
lapsed medulloblastomas arose partly through clonal selection (imposed by surgery and
radiotherapy) of a minor subclone present in the primary tumor. These findings suggest
that treatments aimed at truncal mutations in the primary tumor are unlikely to cure
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patients if they are not present at relapse. Similar screens have been conducted with SB
for genes driving resistance to a BRAF inhibitor in BrafV600E-driven melanoma in an
autochthonous model [147] and with PB revealing convergent mutations in Trp53 as a
resistance mechanism of allografted tumors to MDM2 inhibitors [148]. Future trans-
poson mutagenesis screens to identify the molecular players driving tumor recurrence
in other cancer treatment contexts, including immunotherapies, are warranted.
CRISPR provides a powerful alternative for studying genes driving either resistance
or sensitivity to therapy in vivo. Genes mediating sensitivity or resistance to therapy
can often be identified in the same CRISPR screen by analyzing sgRNAs that are de-
pleted or enriched respectively, maximizing gene discovery. Various computational ap-
proaches have been developed to interpret biologically significant genes in these
contexts [149, 150]. A study employing dCas9-trancriptional activators to perform a
gain-of-function screen in a syngeneic immunocompetent transplant model discovered
Chek2 transcriptional activation leads to increased sensitivity of B-cell acute lympho-
blastic leukemia (B-ALL) to the chemotherapy temozolomide, slowing down bone
marrow relapse [151]. Also, the druggable oncogene KPNB1 was identified in a loss-of-
function CRISPR screen in a xenograft model; KPNB1 inhibition reduced epithelial
ovarian cancer growth in vivo [152]. More recently, Li and colleagues used a multi-
plexed lentiviral approach to deliver sgRNAs against tumor suppressors in a Kras-
driven autochthonous lung cancer mouse model; tumors were treated with a panel of
drugs, and the screen identified Keap1 mutations as a resistance mechanism to carbo-
platin treatment [153], highlighting that cancer cell sensitivity to drugs can be
genotype-specific.
It is now recognized that small-molecule inhibitor drug screens suffer from off-target
toxicity: some drugs kill cells even when their putative genetic targets are mutated by
CRISPR-Cas9 [154, 155]. Although this has only been shown for a selected set of drugs,
this may partially explain why pre-clinical oncology drugs often fail in cancer patients.
In comparison, CRISPR-Cas9 has low off-target effects [98, 156], making drug target
identification more specific.
The immune environment and immunotherapy genetic targets
The immune system is important for suppressing most potentially cancerous cells from
ever forming tumors by recognizing and destroying them at early stages. Cancers that
arise have therefore bypassed this critical immune surveillance, likely because immuno-
genic clones have been removed leaving weakly immunogenic variants to progress, so
called immunoediting [133]. This hypothesis has been supported by cancer transplant-
ation experiments in mice [157] and more recently from human cancer genome se-
quence data [158]. Although the mechanisms of cancer immune escape are far from
fully understood, a prominent example is through T cell suppression by cancer cell up-
regulation of PD-L1 [159], which is exploited clinically in several cancers with major
success [160].
A PB screen in T cells discovered PDCD1, which encodes PD-1, as a key suppressor
of oncogenic T cell signaling that prevents development of T cell lymphoma in an au-
tochthonous mouse model; human lymphomas contain deletions in this gene in up to
30% of cases, confirming clinical relevance [161]. Although PD-1 is well-established as
an immunotherapeutic target, this study showed how it also acts as a TSG by
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increasing levels of PTEN. Accordingly, loss of PDCD1 leads to increased PI3K-AKT
signaling that contributes to T cell lymphoma development.
Moreover, efforts are underway to define further targets on T cells. To define novel
membrane targets on CD8+ T cells that enhance killing of glioblastoma cells, Ye et al.
developed a hybrid genetic screening platform where an SB transposon carrying an
sgRNA library is nested in an ssAAV. This enables efficient genomic integration of the
sgRNA cassette for the screen readout. The AAV-SB-CRISPR library was transduced
into Cas9-expressing mouse CD8+ T cells, which were transplanted into mouse brain
tumors; validation of the screen hits was performed by adoptive transfer of CD8+ T
cells with Pdia3, Mgat5, Emp1, or Lag3 knockouts, which improved survival of GBM-
bearing mice [162].
Other efforts are focusing on identifying targets on cancer cells that more effectively
engage T cells. A CRISPR screen set out to identify genes which can sensitize melan-
oma to PD-1 inhibition or make it more resistant [13]. A pooled sgRNA library target-
ing over 2000 genes (including plasma membrane proteins and those for antigen
presentation) was transduced into murine melanoma cells expressing Cas9, which were
then transplanted into mice. Knockout of PTPN2, which encodes for a protein tyrosine
phosphatase, unexpectedly led to improved efficacy of immunotherapy by increasing
interferon-gamma-mediated effects on antigen presentation. Another CRISPR screen
used an sgRNA library focusing on epigenetic regulators in a syngeneic lung cancer
transplant model, identifying Asf1a sgRNAs as being significantly depleted, and valid-
ation studies confirmed that Asf1a knockout synergized with anti-PD1 therapy to slow
tumor progression by promoting T cell activation [15]. Such screening approaches can
feasibly be tailored to discover new therapeutic targets for immunotherapy in other
cancer contexts [163].
As genetic and epigenetic alterations accumulate during tumor evolution, they have
potential to generate an anti-tumor immune response and rejection if these tumor-
associated antigens (TAA) are adequately presented [164]. However, most such TAAs
are inadequately presented and there is usually neoantigen loss [165], allowing cancer
to evolve whilst evading the immune system. Recent work has leveraged CRISPRa for
multiplexed activation of TAAs to enhance anti-tumor immunity. Injection of an
sgRNA library targeting known mutated genes into mouse cancer cells expressing
dCas9-transcriptional activators led to increased expression and subsequent presenta-
tion of TAAs [166]. Tumor regression occurred because of increased T cell infiltration
and tumor cell destruction in this transplant model. These screens illustrate the thera-
peutic potential of CRISPRa to augment anti-tumor immunity based on detailed know-
ledge of an individual patient’s cancer gene profile.
In summary, functional genomic screens are generating unprecedented insights into
immune regulators of oncogenesis and beginning to pinpoint new immunotherapy
targets.
Future directions for transposon and CRISPR screens
The large-scale data being provided through human oncogenomic studies and in vitro
screens will require complementary advances in autochthonous mouse models and
in vivo screens to provide deeper insights into cancer biology. Here, we highlight areas
for future development in functional genomic screens in cancer.
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Although most screens have focused on protein-coding genes, these account for only
2% of the human genome, demanding exploration of non-coding genomic regions
[167–169], of which enhancers (genetic elements regulating transcription of distant
genes by chromatin looping) make up a large part and can contribute to oncogenesis
[170]. CRISPR screens can be used to characterize functional enhancers, at least
in vitro, by targeting Cas9 to transcription factor binding sites in enhancer regions
[171]. Application of such technology in vivo and for therapeutic resistance investiga-
tions is worthwhile future lines of study.
Critical developments needed for functional interrogation of cancer evolution are
precision-modeling of cancer genetic and epigenetic alterations, multiplexing of cancer
drivers, and technologies for controlling the temporal order of mutations. The use of
dCas9-transcriptional activator mice will enable CRISPR screens to identify oncogenes
in vivo [172], and we anticipate the development of PB or SB transposons with purely
activating sequences could allow this to be performed with insertional mutagenesis.
Given that the type of alteration may influence their oncogenic potential, mice express-
ing CRISPR base-editors may be developed to screen multiple specific point mutations
in autochthonous settings, and mice engineered to express dCas9 fused to DNA meth-
yltransferases may enable screens for epigenetic drivers. It is conceivable that more
complex genetic changes such as chromosomal rearrangements may be amenable to
high-throughput in vivo screens with advances in CRISPR technology. With the rapid
progress in multiplexed CRISPR technologies [173], expression of many gRNAs per cell
will allow us to discover synergistic gene interactions hidden within complex cancer
genetic networks. Moreover, we envision the use of several Cas enzymes in tandem
[174] may enable CRISPR screens to detect both oncogenes and TSGs in vivo. Indu-
cible transposon systems can be engineered to switch on transposition at particular
times during development or adulthood to interrogate the role of timing of mutations
on cancer development [175]. Similarly, inducible systems regulating the expression of
Cas9 by external trigger signals (i.e., small molecules, light, or temperature) have been
developed [176]. Also, engineering of CRISPR constructs with multiple sgRNAs whose
expression can be switched from one sgRNA to another by inducible expression of Cre
is a step in this direction [177], as are in vivo inducible lineage tracing tools that allow
tracking of clonal origins of cell populations in high-resolution [178].
To overcome some limitations with CRISPR library delivery to tissues, engineered
mosaic mice harboring germline floxed sgRNAs linked together in tandem are in devel-
opment, with one sgRNA expressed per cell following Cre-mediated recombination
[179]. Double-stranded AAVs (dsAAVs), which result from a mutation on one of the
viral inverted terminal repeats (ITR), have provided further improvements in viral
transduction efficiency and CRISPR-mediated genome editing, although at the cost of a
reduced package capacity (~ 2.5 kb) compared to ssAAVs [180]. The integration of SB
or PB transposons carrying CRISPR libraries within the ITRs of AAVs allows the gen-
omic integration of the sgRNA cassettes for their easy detection [162], holding promise
for large-scale cancer CRISPR screens.
With the advent of single-cell sequencing, intratumor heterogeneity can be interro-
gated by searching for combinations of sgRNAs or gene-transposon fusion transcripts
respectively across thousands of cells in a tumor and matching these with phenotypes
inferred from cells’ transcriptomes. Refinements in technology may further enable
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screens to be performed directly in immune cells in vivo to identify novel regulators of
immune activation in cancer as potential immunotherapy targets. Ultimately, screens
that are tailored to patient-specific genetic profiles will yield personalized cancer driver
information that can inform precision therapeutics. As an example, human tissue orga-
noids (engineered to express Cas9) can be transduced with a CRISPR library of a pa-
tient’s mutated genes and transplanted into mice to determine the effects of individual
mutations on clonal growth dynamics [181]. We envision that development of a patient
“avatar” approach [11], employing personalized gene libraries for screens, will refine
therapeutic testing strategies to more accurately model the influence of drugs for indi-
vidual patients in the clinic.
The power of large-scale transposon mutagenesis and CRISPR screens, made more
relevant with recent and future developments, will equip us with the tools needed for
gaining unprecedented insights into functional drivers of cancer evolution and thera-
peutic targets for clinical translation.
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